Finoriq research workspace
Xeris Biopharma Holdings, Inc. (XERS) Historical Metrics
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing. Review XERS fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
- Company
- Xeris Biopharma Holdings, Inc. (XERS)
- Ticker
- XERS
- Market Cap
- $1.5B
- Latest Price
- $8.615
- Industry
- Biotech & Pharma
Xeris Biopharma Holdings, Inc. (XERS) Current Valuation Metrics
Static valuation preview for Xeris Biopharma Holdings, Inc. (XERS). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/EMarket cap divided by latest TTM net income. | 2,691x | Net Income | TTM FY 2025 |
| P/SMarket cap divided by latest TTM revenue. | 5.11x | Revenue | TTM FY 2025 |
| P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow. | 52.1x | Operating Cash Flow | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | 0.04% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | 1.9% | Operating Cash Flow | TTM FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.